Evidence map›Paper›PMID 8666926›Full record

ArticleThe Journal of experimental medicine1996

Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin.

M J Maeurer, D Martin, W Walter, K Liu, L Zitvogel, K Halusczcak, H Rabinowich, R Duquesnoy, W Storkus, M T Lotze

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in The Journal of experimental medicine, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 154 citations in OpenAlex.

  1. Trial
  2. Trial
  3. γδ T cells in colorectal and liver cancer.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  4. Article
  5. Harnessing Vδ1Frontiers in immunology · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

M J MaeurerDepartment of Medical Microbiology, University of Mainz, Germany.
D Martin
W Walter
K Liu
L Zitvogel
K Halusczcak
H Rabinowich
R Duquesnoy
W Storkus
M T Lotze
Johannes Gutenberg University Mainz · DE

Funding

GENE THERAPY OF CANCER-IMMUNOLOGICAL APPROACHESP01CA059371 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOTZE, MICHAEL T · 1992 to 1993
–
T CELL RECEPTOR USAGE IN MELANOMA AND ITS PRECURSORSR55CA056088 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOTZE, MICHAEL T · 1992 to 1992
–
NCI NIH HHS CA-56088NCI NIH HHS CA-57804NCI NIH HHS CA-59371
6 · The paper itself

Abstract

gammadelta T cells can be grouped into discrete subsets based upon their expression of T cell receptor (TCR) variable (V) region families, their tissue distribution, and their specificity. Vdelta2+ T cells constitute the majority of gammadelta T cells in peripheral blood whereas Vdelta1+T cells reside preferentially in skin epithelium and in the intestine. gammadelta T cells are envisioned as first line host defense mechanisms capable of providing a source of immune effector T cells and immunomodulating cytokines such as interleukin (IL) 4 or interferon (IFN) gamma. We describe here the fine specificity of three distinct gammadelta+ tumor-infiltrating lymphocytes (TIL) obtained from patients with primary or metastatic colorectal cancer, that could be readily expanded in vitro in the presence of IL-1beta and IL-7. Irrespective of donor, these individual gammadelta T cells exhibited a similar pattern of reactivity defined by recognition of autologous and allogeneic colorectal cancer cells, renal cell cancer, pancreatic cancer, and a freshly isolated explant from human intestine as measured by cytolytic T cell responses and by IFN-gamma release. In contrast, tumors of alternate histologies were not lysed, including lung cancer, squamous cell cancer, as well as the natural/lymphocyte-activated killer cell-sensitive hematopoietic cell lines T2, C1R, or Daudi. The cell line K562 was only poorly lysed when compared with colorectal cancer targets. Target cell reactivity mediated by Vdelta1+ T cells was partially blocked with Abs directed against the TCR, the beta2 or beta7 integrin chains, or fibronectin receptor. Marker analysis using flow cytometry revealed that all three gammadelta T cell lines exhibit a similar phenotype. Analysis of the gammadelta TCR junctional suggested exclusive usage of the Vdelta1/Ddelta3/Jdelta1 TCR segments with extensive (< or = 29 bp) N/P region diversity. T cell recognition of target cells did not appear to be a major histocompatibility complex restricted or to be correlated with target cell expression of heat-shock proteins. Based on the ability of some epithelial tumors, including colorectal, pancreatic, and renal cell cancers to effectively cold target inhibit the lysis of colorectal cancer cell lines by these Vdelta1+ T cell lines, we suggest that intestinal Vdelta1+ T cell lines, we suggest that intestinal Vdelta1+ T cells are capable of recognizing cell surface Ag(s) shared by tumors of epithelial origin.

Indexed as

Amino Acid SequenceAnimalsAntigens, NeoplasmBase SequenceCell Adhesion MoleculesCell LineColorectal NeoplasmsCulture TechniquesHumansInterferon-gammaInterleukin-1Interleukin-7Kidney NeoplasmsLymphocytes, Tumor-InfiltratingMiceMolecular Sequence DataAntigens, NeoplasmCell Adhesion MoleculesInterferon-gammaInterleukin-1Interleukin-7Receptors, Antigen, T-Cell, gamma-deltaRNA, Messenger

Identifiers

PMID8666926
PMCPMC2192504
OpenAlexW2116689616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.